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Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 
1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe 
autologous virus-targeting vaccines, the powerful immunogenicity of VLPs has been also 
harnessed to generate immune response against heterologous and even self-antigens 
(2–4). Linking adjuvants to VLPs displaying heterologous antigen ensures simultaneous 
delivery of all vaccine components to the same antigen-presenting cells. As a conse-
quence, antigen-presenting cells, such as dendritic cells, will process and present the 
antigen displayed on VLPs while receiving costimulatory signals by the VLP-incorporated 
adjuvant. Similarly, antigen-specific B cells recognizing the antigen linked to the VLP are 
simultaneously exposed to the adjuvant. Here, we demonstrate in mice that physical 
association of antigen, carrier (VLPs), and adjuvant is more critical for B than T cell 
responses. As a model system, we used the E7 protein from human papilloma virus, 
which spontaneously forms oligomers with molecular weight ranging from 158 kDa to 
10 MDa at an average size of 50 nm. E7 oligomers were either chemically linked or 
simply mixed with VLPs loaded with DNA rich in non-methylated CG motifs (CpGs), a 
ligand for toll-like receptor 9. E7-specific IgG responses were strongly enhanced if the 
antigen was linked to the VLPs. In contrast, both CD4+ and CD8+ T cell responses as 
well as T cell-mediated protection against tumor growth were comparable for linked and 
mixed antigen formulations. Therefore, our data show that B cell but not T cell responses 
require antigen-linkage to the carrier and adjuvant for optimal vaccination outcome.
Keywords: VlPs, vaccines, hPV, cpg, adjuvant
inTrODUcTiOn
Most prophylactic vaccines are designed to induce strong antibody responses, while many thera-
peutic vaccines against chronic viral infections and cancer aim to induce T cell responses (5, 6). 
However, for many vaccines currently under development, this dictum is challenged, and strong 
B and T cell responses are likely required to achieve protection. Thus, understanding the rules that 
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govern induction of B versus T cell responses and identifying 
commonalities and differences between them represents an 
important goal in vaccinology and immunology.
Formulation of vaccines in adjuvants usually enhances 
both B and T helper (TH) responses (7). However, it is often 
unclear whether the adjuvants enhance B cell responses 
directly or indirectly, via enhancing follicular TH cell 
responses. We have recently shown that the adjuvant CpGs 
linked to antigen enhances B cell responses by activating B 
cells directly through TLR9 recognition (8, 9), which required 
internalization of the CpG. By contrast, CpGs mixed with 
antigen may primarily enhance B cell responses by facilitat-
ing Th cell activation, thereby increasing antibody responses 
indirectly (10–12). As a general rule, it is important that the 
immunological target cells [dendritic cells (DCs) or B cells] 
are simultaneously activated by the adjuvant and exposed to 
the antigen (5, 13). One way to ensure co-exposure to antigen 
and adjuvant is the physical linkage of the two components. 
Something readily achieved by conjugation with covalent 
chemical bonds or by packaging adjuvant into liposomes or 
virus-like particles (VLPs). However, for good manufacturing 
practice production, covalent linkage might be a complicated 
and costly endeavor, especially if the antigen is complex or 
if the goal is patient-specific vaccination. Hence, a simple 
admixed formulation could be advantageous under these 
circumstances.
The trafficking of antigen from the periphery to lymph nodes 
(LNs) or the spleen is essential to drive T cell and B cell activa-
tion (5), and it is well established that one of the main factors 
governing influx to the LNs is the size of the particles (14–16). 
Particles in the nanometer range can flow freely within the 
lymph, rapidly reaching LNs where they can encounter relevant B 
cells and APCs that will activate CD4+ and CD8+ T cells (17–19). 
By simply mixing antigens and adjuvants of similar size, it may 
be possible to target the same individual cells within the LNs. 
To test this, we generated particulate adjuvants and antigens of 
similar size, mixed them freely before injecting the formulation 
into mice, then observed if they indeed were draining to the same 
cells within LNs. As adjuvant, we used VLPs derived from Qβ 
bacteriophages packaged with CpGs, having a size of 30 nm. The 
recombinant oncoprotein E7 derived from the human papilloma 
virus (HPV) was chosen as the target antigen as it forms oligom-
ers with a size of around 50 nm (20). To test the impact of antigen 
size and co-drainage, we also used the immunodominant peptide 
E749–57 derived from the E7 protein, representing a H2-Db-
restricted CTL epitope (12). We found that covalent linkage 
was essential for maximal B cell for peptide and particle-based 
vaccine responses, regardless of the size of the antigen. In con-
trast, an admixed formulation of E7 oligomers with CpG-loaded 
VLPs was sufficient to induce optimal CD4+ and CD8+ T cell 
responses that proved to be protective as a therapeutic vaccine 
when tested in an HPV tumor model. Mixing free E749–57 peptide 
with CpG-loaded VLPs, however, failed to induce strong T cell 
responses, suggesting that adjusted particle size may be sufficient 
to co-deliver antigen and adjuvants to the same DCs for optimal 
T cell induction, eliminating the requirement for the linkage of 
the two entities.
MaTerials anD MeThODs
VlP and e7 Production
HPV-E7 protein containing a short C-terminal GGC linker was 
recombinantly expressed in Escherichia coli, solubilized from the 
inclusion body fraction by 8M urea and purified using affinity and 
size-exclusion chromatography. The denatured protein migrated 
as a 14-kDa single band in reducing SDS-PAGE (data not shown). 
After refolding by dilution and dialysis against NaCl-MES-
containing buffer, E7 protein spontaneously formed oligomers. 
Qβ VLP production and purification have been described in 
detail elsewhere (21).
cpg ODn and antigen sequence
CpGs 1668 with phosphorothioate backbone were purchased 
from Invivogen (sequence: 5′ tccatgacgttcctgatgct 3′). The protein 
and peptides E749–57 were produced in a modified version with 
additional 3 aa (GGC) added to the C terminus E7 (Proimmune, 
UK) to allow coupling to VLPs. E7 protein sequence UniProt 
database: P03129. E749–57 peptide sequence: RAHYNIVTFGGC.
Measurement of anti-e7 and anti-VlP 
antibodies by elisa
Anti-VLP and anti-E7 antibody titers were measured in the 
serum of mice vaccinated 21 days earlier with unmodified VLP. 
A total of 96-well plates were coated overnight with 5 μg/mL of 
unmodified VLP or 5 μg/mL of E7 oligomers. After blocking for 
2  h with 2% bovine serum albumin phosphate-buffered saline 
(PBS), serum obtained from vaccinated or control mice (diluted 
1:500 to 1:12,500) was added and plates were incubated for 2 h at 
room temperature. After washing the plates three times with PBS-
0.05% Tween, horseradish peroxidase-labeled goat anti-mouse 
immunoglobulin G (IgG-HRP) (Jackson ImmunoResearch, UK) 
was added for 1  h, followed by the addition of 3,3′,5,5′-tetra-
methylbenzidine (TMB) Sigma, as a substrate before reading the 
optical density (OD) at 450 nm (OD450). Titers are expressed as 
serum dilutions at the half-maximal OD (OD50).
association elisa
Plates (Nunc-Immuno MaxiSorp) were coated with anti-E7 
antibody, each of the vaccine preparations were added at a con-
centration corresponding to 60 ng/mL of E7 protein. Following 
washing and incubations, anti-Qβ monoclonal antibody was 
added followed by secondary detection antibody goat anti-mouse 
IgG-HRP and TMB. Data expressed in OD450.
Vaccine Preparation
Vaccines were prepared by chemical coupling as described else-
where (2). Purified Qβ VLPs (2 mg/mL in PBS) were derivatized 
by a 1-h incubation at room temperature with a 10-fold molar 
excess of succinimidyl-6-(β-maleimidopropionamido)hexanoate 
(Pierce, Rockford, IL, USA). Free cross-linker was removed by 
diafiltration with Amicon Ultra Centrifugal Filters, 100  kDa 
MWCO. Derivatized Qβ VLPs and E749–57-GGC (peptide at five-
fold molar excess) or E7 protein were then incubated for 3 h at 
room temperature to allow cross-linking. Unbound material was 
FigUre 1 | size characterization of Qβ virus-like particles (VlPs) and e7 protein. (a) Size-exclusion chromatography of refolded E7 in buffer without 
reducing agent (upper panel) using TSKgel G4000SW column (resolution between 2 × 104 and 7 × 106 Da). Refolded E7 (bottom panel) forms oligomers with elution 
time between 9.3 and 15 min. (B) Size-exclusion of Qβ VLPs in a S500 column eluted with phosphate-buffered saline. Narrow peak shows narrow size distribution. 
(c) Schematic representation of the system of antigens. VLPs have an average size of 30 nm, E7 protein of 50 nm, and the peptide has a size of 1.7 kDa. The plus 
signal (+) indicates the mixed formulation of VLP and antigen, the dash (–) indicates chemical coupling of antigen and VLP. (D) Immunoplate assay demonstrating 
the absence of physical association between VLP and E7 protein in the mixed formulation. Plates were coated with anti-E7 antibody, each of the vaccines 
preparation was added at a concentration corresponding to 60 ng/ml E7 protein. Following washing and incubations, anti-Qβ monoclonal were added followed by 
detection antibody. Data expressed in optical density (OD).
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removed by diafiltration with Amicon Ultra centrifugal filters, 
100 kDa MWCO for the peptide and size exclusion for the E7 
protein. Efficiency of cross-linking was analyzed by SDS-PAGE.
Packaging of cpg into Qβ VlPs
Performed as described elsewhere (22). Briefly, bacterial RNA 
trapped into VLPs during recombinant expression was digested 
with RNAse A (Merck) for 5 h at 37°C. RNAse-treated VLPs were 
combined with 120  nM/mL of CpG and incubated for further 
3 h at 37°C. Excess of CpG was removed by dialysis against PBS.
immunization and Trafficking 
experiments
C57BL/6 mice (9–12  weeks old; Harlan) were injected s.c. 
with 80 μg of either vaccine formulation. Blood was collected 
from the tail vein and serum and PBMCs separated for further 
analysis.
E7 protein or E749–57 was labeled with AlexaFluor 488 
C5-maleamide as described by the manufacturer and with Qβ 
labeled with AlexaFluor 647 or PE as instructed by the manufac-
turer (all from Thermo Fischer). C57BL/6 mice (9–12 weeks old; 
Harlan) were injected s.c. with 30 μg of VLP and peptide into the 
hind leg.
All mouse experiments have been performed in accordance 
with the local welfare legislation and under valid animal experi-
mentation licenses.
cells and Flow cytometry
Popliteal and inguinal LNs were isolated and a single-cell suspen-
sion was prepared by incubating LN with 1 mg/mL collagenase 
D (Roche) and 0.04  mg/mL DNase I (Boehringer) in 5% FSC 
containing DMEM, for 30 min at 37°C. Organ pieces were passed 
through a 70-μm cell strainer and stained for cell-specific mark-
ers. The following fluorochrome-labeled antibodies were used: 
CD11c, CD8a (all from eBioscience), F4/80, Live/Dead Aqua cell 
stain (all from Life Technologies).
Spleens were isolated smashed through a 70-μm cell strainer 
using the plunger of a syringe (Falcon), red blood cells were lysed 
FigUre 2 | Biochemical analysis of the coupling of Qβ and hPV.e7. 
HPV.E7 (lane 1 and 4), SMPH reacted Qβ (2 and 5), and coupled Qβ-E7 
(3 and 6) were separated by SDS-PAGE under reducing conditions and 
analyzed by Western blot. HPV-E7 was detected in lanes 1–3 by anti-His tag 
antibody (His Tag Ab), and lanes 4–6 were assayed with anti-Qβ specific 
antibody (Qβ Ab).
4
Gomes et al. Antigen Size and T Cell Responses
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 226
with ACK solution (Lonza). The following fluorochrome-labeled 
antibodies were used: CD3, CD8a, Live-Dead dye, IFNγ, TNFα, 
and IL-17 (eBioscience).
Primary culture of DCs from LNs of a naïve mice were har-
vested and incubated for 24 h with 10 nM of E749-51 conjugated 
with Alexa488 and 1 μg/mL of Qβ conjugated with Alexa647. 
CD11c+ F4/80− DCs were subsequently analyzed by flow cytom-
etry for uptake of peptide and Qβ.
Tumor Model
Female C57BL/6 mice at age of 10–11 weeks were injected with 
1.5 ×  105 TC-1 cells expressing HPV16 E7 oncoprotein. Eight 
days post injection of tumor cells, mice developed palpable 
tumors and were subjected to a weekly immunization schedule 
with E7 coupled or mixed to Qβ(1668) for 49 days. Tumor size 
was recorded daily and was calculated as follows: W*W*L/2, 
where W is tumor width (centimeters) and L is tumor length 
(centimeters). Mice showing signs of suffering or reaching tumor 
size larger than 1,000 cm3 were euthanized.
resUlTs
characterization of Qβ-VlPs and e7
Size-exclusion chromatography analysis of refolded E7 showed 
a wide distribution elution profile corresponding to molecular 
weights between 17  kDa and 10  MDa (void volume of the 
column, Figure 1A, upper panel). The refolded E7 was treated 
under reducing conditions, which narrowed the molecular 
weight distribution to a major peak with average size of 
670 kDa (Figure 1A, bottom panel) and demonstrated the role 
of disulfide bonds in E7 multimerization, as described else-
where (20). The 14 kDa capsid protein of the Qβ bacteriophage 
is expressed in E. coli and self-assembles to form a VLP with 
molecular weight of approximately 3  MDa. Electron micros-
copy and dynamic light scattering (not shown) demonstrates 
that Qβ VLPs are single particles with average diameter of 
30 nm. The size-exclusion profile demonstrated a narrow size 
distribution of the VLP on a S500 column (GE) (Figure 1B). 
Thus, Qβ VLPs and non-reduced E7 oligomers exhibit roughly 
comparable sizes of 30–50 nm.
Qβ and e7 Protein are Physically 
associated by chemical coupling but  
not by Mixing
In order to compare the immunogenicity of mixed and cova-
lently linked antigen and VLP, the E7 protein containing a 
short cysteine-containing linker (-GGC) was chemically cross-
linked via the free cysteine to surface lysine on Qβ using the 
hetero-bi-directional cross-linker, SMPH. The efficiency of the 
cross-linking was assessed by separation on SDS-PAGE under 
reducing conditions and analyzed by Western blot (Figure 2). 
Alternatively, purified Qβ and E7 protein were simply mixed. 
The model of mixed and coupled formulations is represented in 
Figure 1C. To assess whether mixing would result in spontaneous 
association of Qβ to E7 oligomers, a sandwich ELISA assay was 
performed using anti-Qβ VLP capture antibodies and anti-E7 
detection antibodies. The assay demonstrated that E7 was only 
associated with Qβ VLPs upon chemical coupling, while simple 
mixing did not result in any physical association (Figure 1D). To 
ensure that loading of VLPs with CpGs did not alter the bind-
ing properties of VLPs, the ELISA was repeated with Qβ VLPs 
loaded with B-type CpG 1668 (Qβ (1668)). Similarly, no associa-
tion between E7 and Qβ VLPs could be observed (Figure 1D). 
VLPs loaded with CpG are represented as Qβ(1668), while “Qβ” 
will be used to indicate unmodified VLPs (naturally loaded with 
E. coli-derived ssRNA).
linkage of Qβ and e7 is not required  
for Uptake by the same Dcs
Drainage of Qβ and E7 was assessed by labeling particles with 
Phycoerythrine (PE) and Alexa488, respectively. Flow cytometry 
analysis demonstrated that a subpopulation of resident DCs of 
draining LNs simultaneously took up both E7 and Qβ VLPs 
(Figure  3A). A total of 23% of cDCs (CD11chighF4/80−) from 
the popliteal LN were double positives for Qβ and the antigen 
E7-Alexa488. Thus, antigen and adjuvants, i.e., E7 and Qβ VLPs, 
were taken up simultaneously in vivo by the same DCs.
To confirm the hypothesis that antigen and VLP size was the 
limiting factor on antigen and VLP distribution, the E7 derived 
peptide H2-Db E749–57 was used as antigen instead of the E7 
FigUre 3 | Draining of Qβ virus-like particle (VlP) and antigens to lns. (a) Qβ-VLP mixed with E7 oligomers are taken up by the same population of DCs in 
the draining lymph nodes. Mice were injected either with Qβ-VLP-Alexa488 or E7-phycoerythrin (PE) or a mixture of both particles (100 μg of each). The uptake of 
the fluorescent proteins into DCs of the draining lymph node (popliteal) was analyzed by flow cytometry. Frequency plot is gated on DCs (CD11c+ F4/80−). 
(B) Frequency plot of cells from draining LNs 24 h postinjection with 100 μg of Qβ-Alexa647 and 100 μg of E749–57 peptide labeled with Alexa Fluor 488. (c) In vitro 
uptake of Qβ-Alexa647 and E749–57 Alexa488. Single cell preparation draining LN of naïve C57BL/6 mice was prepared and pulsed for 24 h with 1 μg/mL VLP and 
10 nM of peptide. Frequency plot is gated on DCs (CD11c+ F4/80−).
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protein. Injection of free peptide E749–57 labeled likewise with 
Alexa488 and Qβ VLPs labeled with Alexa647 did not result in 
simultaneous uptake by DCs in draining LNs (Figure 3B). As a 
matter of fact, the peptide could not be found in LNs 24 h after 
injection, indicating that small peptides do not drain efficiently 
to LNs and are not efficiently transported by DCs.
To exclude potential methodological limitations in visualizing 
peptide interaction with DCs by flow cytometry, an in vitro puls-
ing experiment was performed. Primary cultures of DCs from 
LNs of a naïve mice were incubated for 24  h with the peptide 
E749-51 conjugated to Alexa488 and Qβ conjugated to Alexa647. 
CD11c+ F4/80− DCs were subsequently analyzed by flow cytom-
etry for uptake of peptide and Qβ. As shown in Figure 3C, almost 
50% of the DCs simultaneously interacted with the peptide and 
Qβ, which confirmed the capacity of small peptides to interact 
with DCs in  vitro and suggested that subcutaneously injected 
small peptides do not efficiently traffic to the LN.
Packaging of cpg into VlPs is necessary 
to induce T cell responses
The contribution of the vaccine components for generation of 
CD4+ and CD8+ T cell responses was investigated by injecting 
mice with E7 protein either alone or mixed with CpG and 
Qβ(1668) either coupled or mixed with E7. The production 
of IFNγ by CD4+ and CD8+ T cells was measured 8 days after 
vaccination. E7 alone or mixed with free CpG induced low 
percentage of E7-specific T cells. E7 protein mixed or coupled 
with Qβ(1668) efficiently induced T cells producing IFNγ 
demonstrating the superior T cell immunogenicity of a vac-
cine containing VLPs-packaged CpGs (Figures  4A,B). More 
importantly, levels of CD4+ and CD8+ T cell responses induced 
by E7 protein either mixed or coupled to Qβ(1668) were 
similar, suggesting that chemical association of the antigen 
and adjuvant is dispensable for priming (Figures 4A,B) T cell 
responses.
Mixing of antigens and cpg-loaded VlP 
of similar size is sufficient for induction of 
strong T cell responses
After establishing that Qβ(1668) was necessary to induce IFNγ 
production by CD8+ T cells in response to E7 and that DCs 
simultaneously take up antigen and VLP if simply mixed, it 
was investigated whether such formulation was sufficient for 
induction of protective T cell responses or whether covalent 
FigUre 4 | coupling of similar size antigens to VlPs is not required for cytokine production by T cells. C57BL/6 mice were immunized, and T cell 
responses were assessed 8 days later. (a) IFNγ production by CD4+ T cells after immunization with E7 protein, E7 mixed with 1668, Qβ(1668) + E7 mixed and 
Qβ(1668) − E7 coupled. (B) IFNγ production by CD8+ T cells after immunization with E7 protein, E7 mixed with 1668, Qβ(1668) + E7 mixed, and Qβ(1668) − E7 
coupled. Mice were immunized with mixed or coupled vaccines. Boost was administered 70 days after first dose, blood was collected on days 0, 8, 71, and 78 for 
IFNγ measurements. (c) Kinetics of IFNγ production by CD4+ T cells from blood. (D) Kinetics of IFN production by CD4+ T cells from blood. Data represented as 
mean + SD n = 5 mice per group.
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linkage of E7 oligomers to Qβ(1668) VLPs was necessary. First, 
the kinetics and duration of the response were measured. E7 
was either chemically coupled to or mixed with Qβ(1668) and 
C57BL/6 mice were immunized s.c. in a prime-boost scheme 
70 days apart. T cell responses were followed in the blood by 
intracellular cytokine staining for IFNγ. Both experimental 
groups mounted strong primary CD4+ and CD8+ T cell 
responses that had declined by day 70 and were strongly 
increased after the boost injection (Figures  4C,D, respec-
tively). CD4+ and CD8+ T cells from the blood were analyzed 
by intracellular cytokine staining upon in vitro stimulation on 
day 78.
To further investigate the cytokine production of splenic T 
cells, spleens were collected on day 78. Both vaccination regimens 
induced strong CD8+ and CD4+ T cell responses expressing 
multiple cytokines (Figure 5) and induction of multifunctional 
CD4+ T cells producing IFNγ, TNFα, and IL-17 (Figure 5A,B) 
were observed. For CD8+ T cells, a strong induction of TNFα and 
IFNγ-producing T cells was detected (Figure 5D,E). The number 
of tetramer-positive cells was roughly similar to the frequency 
of IFNγ-producing CD8+ T cells (Figure 5E). Thus, as observed 
in the blood, linked E7 protein induced similar frequencies of 
cytokine-producing T cells compared to the mixed formulation 
in splenic T cells (Figure 5).
In marked contrast to the results obtained with particulate 
E7 proteins, for small peptides, linkage to the VLP was essential. 
Specifically, mice immunized with the peptide E749–57 coupled to 
Qβ(1668) generated strong CD8+ T cell responses. In contrast, 
E749–57 mixed to Qβ(1668) failed to induce good production of 
IFNγ and TNFα by CD8+ T cells significantly above background 
(Figure 6).
Mixing of e7 Protein with Qβ (1668) is 
sufficient for eradication of established 
Tumors
In order to assess the therapeutic capacity of the vaccine-induced 
T cells, mice were injected with TC-1 cells expressing HPV16 
FigUre 5 | coupling of similar size antigens to VlPs is not required for cytokine production by T cells. (a) TNFα and TNFγ production by CD4+ T cells 
upon vaccination with Qβ(1668) − E7. (B) IL-17 and TNFγ production by CD4+ T cells upon vaccination with Qβ(1668) − E7. (c) Cytokine production by CD4+ 
T cells upon vaccination with Qβ(1668) − E7. (D) Frequency of cytokine producing cells among CD8+ T cells upon in vitro stimulation. (e) Cytokine production by 
E7-tetramer specific CD8+ T cells. (F) Frequency of cytokine producing cells among CD4+ T cells upon in vitro stimulation.
FigUre 6 | coupling of small peptides and VlP is required for activation of cD8+ T cells. C57BL/6 female mice were immunized twice (days 0 and 7) s.c. 
with 50 μg of coupled or mixed Qβ(1668) and E749–57. Spleens were harvested on day 14 for cytokine production. Cells were stimulated for 6 h with peptide and 
analysed by flow cytometry. (a) IFN-γ and TNF-α production by CD8+ T cells upon prime-boost vaccination with mixed (upper panel) and coupled (lower panel) 
versions of Qβ(1668) vaccine. (B) Coupled vaccine (bottom) induces multifunctional CD8+ T cells but not mixed (upper). (c) Percentage of CD8+ T cell producing 
IFNγ and TNFα post in vitro stimulation. Data represented as mean plus SEM, n = 5. Cells analyzed by FCM, 1 × 107 cells acquired per sample. Values are plotted 
after subtraction of background values from non-stimulated samples.
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FigUre 8 | covalent linkage is required for optimal responses of B cells. (a) Antibody titters for IgG against E7 expressed in log scale of OD50 on day 71. 
(B) Total IgG titters expressed in log scale of OD50 against Qβ at day 71 measured by ELISA. Mean with SEM in log transformed titters. (c) Antibody titters expressed 
in OD50 against the peptide E749–57. Values as mean (n = 5) plus SEM.
FigUre 7 | simply mixing of similar size antigen and adjuvant is enough for protection against tumor. (a) Tumor growth after tumor challenge in 
immunized mice with mixed and coupled vaccines or controls was monitored over 50 posttumor inoculation. (B) C57BL/6 female mice (n = 5 per group) were 
injected i.v. with 1.5 × 105 TC-1 cells expressing HPV-16 E7 oncoprotein. Crosses indicate the weekly immunization schedule with E7 coupled or mixed to Qβ(1668) 
for 49 days. (B) Percent of survival and tumor growth in immunized groups was monitored over time and represented in a Kaplan–Meier survival curve and analysed 
using the Log-rank test; *P < 0.05.
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E7 oncoprotein. Eight days post injection of tumor cells, mice 
developed palpable tumors and were subjected to a weekly 
immunization schedule with E7 coupled or mixed to Qβ(1668) 
for 49  days (Figure  7A). In untreated mice, as well as mice 
injected with Qβ(1668) only, tumors grew unrestrained and 50% 
of mice reached severity scores requiring euthanasia by day 32 
(Figure 7B). In contrast, both coupled and mixed formulation of 
Qβ(1668) and E7 protein were able to induce strong protection 
against tumor growth resulting in survival rate of more than 80% 
until the end of the study. In an additional study, vaccination with 
E7 mixed with Qβ(1668) extended the survival of tumor bear-
ing mice to more than 3  months (data not shown). Therefore, 
covalent linkage of the E7 to Qβ(1668) VLPs is not required for 
induction of protective T cell responses against solid tumor.
covalent linkage of e7 Oligomers to 
cpg-loaded VlPs is required for 
induction of Optimal B cell responses
In order to understand whether the same rules would apply to 
B cells, the importance of covalent linkage of E7 to Qβ VLPs for 
induction of optimal antibody responses was assessed. Serum 
collected from mice immunized with E7 coupled or mixed 
with Qβ(1668) were analyzed for E7-specific antibody response 
by ELISA. Importantly, only covalent coupling but not simple 
mixing of E7 and Qβ (1668) was able to enhance the antibody 
response against E7 (Figure 8A). Conversely, the antibody levels 
raised against Qβ were higher in the mixed formulation when 
compared to the coupled counterpart (Figure  8B). Antibody 
induction against the E749–57 peptide also required covalent link-
age, as in the absence of linkage, antibody levels induced were 
comparable to the background (Figure 8C). Hence, in contrast 
to T cell responses, B cell responses appear to require physical 
linkage of antigen and adjuvants in order to induce appropriate 
levels of antibody responses irrespective of the size of the antigen.
DiscUssiOn
In the current study, we demonstrated in an HPV model that a 
particulate VLP-based vaccine containing CpG exerts distinct 
adjuvant effects in B and T cells. While for T cells, the concomitant 
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draining of antigen and adjuvant to LNs and subsequent uptake 
by APCs is enough for T cell-mediated cytokine production and 
protection against the expansion of tumors, for B cells, appropri-
ate presentation of antigens by linkage to VLPs is required for 
induction of optimal antibody levels.
This dichotomy may be explained by mechanistic differences 
in the induction of innate and adaptive immune responses. The 
innate arm of the immune system represented by DCs is able to 
recognize certain pathogen and danger-associated patterns (23). 
However, specific receptor–ligand interaction is not required in 
order to induce phagocytosis and activation (24). Thus, DCs will 
non-specifically take up both antigen and VLP. This is strictly 
different for B cells, which take up particles in an antigen-specific 
fashion. For B cells to be exposed to CpGs packaged within VLPs, 
they need to take up the particles via their B cell receptors (BCR), 
which will be followed by internalization of the VLP plus their 
CpG cargo (25). Therefore, E7-specific B cells will fail to take 
up VLPs loaded with CpGs unless E7 is linked to the VLPs. In 
addition to that, VLPs are potent activators of B cells (26, 27) 
and the presentation of the coupled antigens in the surface of the 
VLPs in a geometrically defined and repetitive manner promotes 
cross-linking of the BCR, which helps surpass the threshold for 
cellular activation (28). In the case of large antigens such as E7, 
the coupling is limited by steric hindrance of the proteins, limit-
ing the number of copies of E7 that can be exposed. However, our 
data suggest that even with relatively low valency of the antigen, 
coupling exerts a positive impact on the level of antibodies 
produced.
For priming of T cell responses, activation of the DCs present-
ing the specific antigen is required (29). The simultaneous uptake 
of antigen and adjuvants by DCs, but not by T cells is critical (30). 
However, in contrast to B cells, DCs take up particulate antigens 
non-specifically without need for antigen-specific receptors (31). 
Given that DCs on average can accommodate and take up 70 
particles (at a size of about 30 nm) (32), most DCs will take up 
reasonable numbers of both particle species at the same time. 
Therefore, simple co-exposure of DCs to particulate antigen and 
adjuvants is sufficient for simultaneous uptake of both entities. 
This guarantees that DCs will be appropriately activated provid-
ing optimal signaling to T cells.
Of particular note, the conclusions from this study are in 
agreement with a growing body of evidence that proposes that 
the size of antigens conveys major influence on factors driving 
immunity (14, 15, 17, 18). Peptides are well known to be unable 
to induce relevant immune responses; this is likely a result of inef-
ficient drainage, degradation, or uptake by resident DCs in vivo 
that do not migrate to the LNs. A position that appears to have 
been confirmed here, as administered peptides failed to charge 
LN resident DCs.
Collectively, these observations are important for vaccine 
development, as they elucidate distinct requirements for 
induction of optimal B versus T cell responses and indicate 
that the use of both particulate antigens and adjuvants with 
similar size avoids the necessity of conjugating the two entities 
together. This may be especially important for the development 
of patient-specific vaccines. VLPs are an attractive platform for 
personalized vaccines considering the convenience of produc-
tion and low costs.
Based on the findings of this work, a new advantage is 
attributed to such nanoparticles, as we show that covalent 
linkage of antigen and adjuvants might not be necessary to 
obtain protective tumor-specific T cells. This knowledge can be 
used to design antigens that would not require coupling, which 
would streamline the manufacturing process and increase 
cost-savings. Also, this simple system of mixed and coupled 
vaccines stands as an attractive tool to explore the dynamic of 
humoral and cellular responses and how they interact.
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